Union européenne - français - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (sous forme de phosphate) - myeloproliferative disorders; polycythemia vera; graft vs host disease - agents antinéoplasiques - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polyglobulie de vaquez (pv)jakavi est indiqué pour le traitement de patients adultes atteints de polyglobulie de vaquez, qui sont résistants ou intolérants à l'hydroxyurée. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - comprimés - ruxolitinibum 5 mg ut ruxolitinibi phosphas, lactosum monohydricum 71.45 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.32 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - comprimés - ruxolitinibum 15 mg ut ruxolitinibi phosphas, lactosum monohydricum 214.35 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.97 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - comprimés - ruxolitinibum 20 mg ut ruxolitinibi phosphas, lactosum monohydricum 285.8 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 1.29 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - ruxolitinibum - comprimés - ruxolitinibum 10 mg ut ruxolitinibi phosphas, lactosum monohydricum 142.9 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, hydroxypropylcellulosum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso corresp. natrium 0.65 mg. - myelofibrose, polycythaemia vera, akute graft-versus-host-krankheit - synthetika

Canada - français - Health Canada

novartis pharmaceuticals canada inc - ruxolitinib (phosphate de ruxolitinib) - comprimé - 10mg - ruxolitinib (phosphate de ruxolitinib) 10mg - antineoplastic agents

Canada - français - Health Canada

novartis pharmaceuticals canada inc - ruxolitinib (phosphate de ruxolitinib) - comprimé - 5mg - ruxolitinib (phosphate de ruxolitinib) 5mg - antineoplastic agents

Canada - français - Health Canada

novartis pharmaceuticals canada inc - ruxolitinib (phosphate de ruxolitinib) - comprimé - 15mg - ruxolitinib (phosphate de ruxolitinib) 15mg - antineoplastic agents

Canada - français - Health Canada

novartis pharmaceuticals canada inc - ruxolitinib (phosphate de ruxolitinib) - comprimé - 20mg - ruxolitinib (phosphate de ruxolitinib) 20mg - antineoplastic agents